Literature DB >> 16870456

Drug Guru: a computer software program for drug design using medicinal chemistry rules.

Kent D Stewart1, Melisa Shiroda, Craig A James.   

Abstract

Drug Guru (drug generation using rules) is a new web-based computer software program for medicinal chemists that applies a set of transformations, that is, rules, to an input structure. The transformations correspond to medicinal chemistry design rules-of-thumb taken from the historical lore of drug discovery programs. The output of the program is a list of target analogs that can be evaluated for possible future synthesis. A discussion of the features of the program is followed by an example of the software applied to sildenafil (Viagra) in generating ideas for target analogs for phosphodiesterase inhibition. Comparison with other computer-assisted drug design software is given.

Entities:  

Mesh:

Year:  2006        PMID: 16870456     DOI: 10.1016/j.bmc.2006.06.024

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

1.  Chemical space: missing pieces in cheminformatics.

Authors:  Sean Ekins; Rishi R Gupta; Eric Gifford; Barry A Bunin; Chris L Waller
Journal:  Pharm Res       Date:  2010-08-04       Impact factor: 4.200

2.  Successful identification of key chemical structure modifications that lead to improved ADME profiles.

Authors:  Lourdes Cucurull-Sanchez
Journal:  J Comput Aided Mol Des       Date:  2010-05-09       Impact factor: 3.686

3.  ALOHA: a novel probability fusion approach for scoring multi-parameter drug-likeness during the lead optimization stage of drug discovery.

Authors:  Derek A Debe; Ravindra B Mamidipaka; Robert J Gregg; James T Metz; Rishi R Gupta; Steven W Muchmore
Journal:  J Comput Aided Mol Des       Date:  2013-10-11       Impact factor: 3.686

4.  Herman Skolnik award symposium honoring Yvonne Martin.

Authors:  Wendy A Warr
Journal:  J Comput Aided Mol Des       Date:  2009-12-10       Impact factor: 3.686

5.  Guiding effective decisions: an interview with Matthew Segall, CEO of Optibrium. Interview by Wendy A. Warr.

Authors:  Matthew Segall
Journal:  J Comput Aided Mol Des       Date:  2011-01-12       Impact factor: 3.686

6.  Systemic evolutionary chemical space exploration for drug discovery.

Authors:  Chong Lu; Shien Liu; Weihua Shi; Jun Yu; Zhou Zhou; Xiaoxiao Zhang; Xiaoli Lu; Faji Cai; Ning Xia; Yikai Wang
Journal:  J Cheminform       Date:  2022-04-01       Impact factor: 5.514

7.  Basic primitives for molecular diagram sketching.

Authors:  Alex M Clark
Journal:  J Cheminform       Date:  2010-10-05       Impact factor: 5.514

8.  Automated design of ligands to polypharmacological profiles.

Authors:  Jérémy Besnard; Gian Filippo Ruda; Vincent Setola; Keren Abecassis; Ramona M Rodriguiz; Xi-Ping Huang; Suzanne Norval; Maria F Sassano; Antony I Shin; Lauren A Webster; Frederick R C Simeons; Laste Stojanovski; Annik Prat; Nabil G Seidah; Daniel B Constam; G Richard Bickerton; Kevin D Read; William C Wetsel; Ian H Gilbert; Bryan L Roth; Andrew L Hopkins
Journal:  Nature       Date:  2012-12-13       Impact factor: 49.962

9.  SCRIPDB: a portal for easy access to syntheses, chemicals and reactions in patents.

Authors:  Abraham Heifets; Igor Jurisica
Journal:  Nucleic Acids Res       Date:  2011-11-08       Impact factor: 16.971

Review 10.  A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets.

Authors:  Michael J Wasko; Kendy A Pellegrene; Jeffry D Madura; Christopher K Surratt
Journal:  Front Neurol       Date:  2015-09-11       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.